- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
18 result(s) found for: Antibacterial agent.
Displaying page 1 of 1.
EudraCT Number: 2004-000406-51 | Sponsor Protocol Number: EMD20001 | Start Date*: 2004-09-16 |
Sponsor Name:GlaxoSmithKline | ||
Full Title: A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment o... | ||
Medical condition: Suspected or Confirmed Gram-negative Severe Sepsis in Adults | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) ES (Completed) CZ (Completed) LV (Completed) AT (Completed) HU (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-004860-37 | Sponsor Protocol Number: 280312BS | Start Date*: Information not available in EudraCT |
Sponsor Name:Arcutis Pharmaceuticals | ||
Full Title: A phase IIIb/IV, single-center, randomized, controlled, observer-blind study to assess the effects of topical formulations containing clindamycin-benzoyl peroxide on epidermal functions in subjects... | ||
Medical condition: Healthy volunteer trial to investigate the effects of IDP-110 Gel compared to two marketed products containing cindamycin-benzoyl peroxide on epidermal functions | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-001735-66 | Sponsor Protocol Number: NXL103/2001 | Start Date*: 2007-10-01 | |||||||||||
Sponsor Name:Novexel S. A. | |||||||||||||
Full Title: A double blind, multicentre, multinational, randomized, double dummy, three-arm parallel-group comparative study of the efficacy, safety and tolerance of oral NXL103 (500 mg twice daily) versus NXL... | |||||||||||||
Medical condition: Community-Acquired Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000158-47 | Sponsor Protocol Number: J&P002/2011 | Start Date*: 2012-01-19 |
Sponsor Name:Klin. Abtlg. für Thorax- & Hyperbare Chirurgi | ||
Full Title: Assessment of extracellular concentrations of linezolid and other currently approved antibiotics in patients presenting with severe bacterial lung infection | ||
Medical condition: Subjects who are scheduled to undergo elective open-chest lung surgery will be included in the study. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-006153-41 | Sponsor Protocol Number: J&P004/2008 | Start Date*: 2009-03-30 |
Sponsor Name:Medical university Graz, Department of Plastic Surgery | ||
Full Title: Target site pharmacokinetics of linezolid after repetitive doses in diabetic patients with bacterial foot infection | ||
Medical condition: The study population will consist of a representative group of adult male or female patients with documented diabetes and bacterial soft tissue infection of the foot complicated by osteomyelitis. P... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001605-32 | Sponsor Protocol Number: BPR-CS-008 | Start Date*: 2017-10-06 | |||||||||||
Sponsor Name:Basilea Pharmaceutica International Ltd | |||||||||||||
Full Title: A randomized, double-blind, multicenter study to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and ski... | |||||||||||||
Medical condition: Acute bacterial skin and skin structure infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003741-17 | Sponsor Protocol Number: PMX63-203 | Start Date*: 2012-01-17 | |||||||||||
Sponsor Name:PolyMedix Inc. | |||||||||||||
Full Title: Randomized, Dose Ranging, Active Controlled Efficacy and Safety Evaluation of PMX-30063 As Initial Treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Staphylococcus... | |||||||||||||
Medical condition: Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Staphylococcus aureus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001198-55 | Sponsor Protocol Number: KronLungesyg_COVID_19_protokol_2 | Start Date*: 2020-04-03 | ||||||||||||||||
Sponsor Name:Chronic Obstructive Pulmonary Disease Trial Network (COP:TRIN) | ||||||||||||||||||
Full Title: Proactive Prophylaxis with Azithromycin and Hydroxychloroquine Patients Hospitalized with COVID | ||||||||||||||||||
Medical condition: This trial will investigate infection with coronavirus (COVID-19) in patients who are admitted to hospital | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-011466-29 | Sponsor Protocol Number: CXA 101-03 | Start Date*: 2009-06-18 | ||||||||||||||||||||||||||
Sponsor Name:Calixa Therapeutics Inc | ||||||||||||||||||||||||||||
Full Title: A Multicenter, Double-blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA 101 and Intravenous Ceftazidime in Complicated Urinary Tract Infection, Including Pyelon... | ||||||||||||||||||||||||||||
Medical condition: Complicated Urinary tract Infection including Pyelonephritis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) PL (Completed) CZ (Prematurely Ended) BE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004544-38 | Sponsor Protocol Number: C3601009 | Start Date*: 2020-07-03 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PROSPECTIVE, RANDOMIZED, OPEN-LABEL, COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) AND BEST AVAILABLE THERAPY FOR THE TREATMENT OF SERIOUS INF... | |||||||||||||
Medical condition: SERIOUS INFECTIONS DUE TO MULTI-DRUG RESISTANT GRAM- NEGATIVE BACTERIA PRODUCING METALLO-Β-LACTAMASE (MBL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004590-90 | Sponsor Protocol Number: 3415A-001 | Start Date*: 2012-02-17 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium ... | |||||||||||||
Medical condition: recurrence of Clostridium difficile infection (CDI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) CZ (Completed) BE (Completed) DK (Completed) PT (Completed) AT (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004250-28 | Sponsor Protocol Number: 3074A1-900 | Start Date*: 2006-09-22 |
Sponsor Name:Wyeth Pharmaceuticals, Inc. | ||
Full Title: A MULTICENTER, RANDOMIZED, OPEN-LABEL COMPARISON OF THE SAFETY AND EFFICACY OF TIGECYCLINE WITH THAT OF AMPICILLIN-SULBACTAM OR AMOXICILLIN-CLAVULANATE TO TREAT COMPLICATED SKIN AND SKIN STRUCTURE ... | ||
Medical condition: COMPLICATED SKIN AND SKIN STRUCTURE INFECTION | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) DE (Completed) FR (Completed) IT (Completed) PT (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-006210-14 | Sponsor Protocol Number: GIMEMA01 | Start Date*: 2007-07-12 | |||||||||||
Sponsor Name:UNIVERSITA' DEGLI STUDI DI PERUGIA | |||||||||||||
Full Title: PIPERACILLIN/TAZOBACTAM PLUS TIGECYCLINE VS. PIPERACILLIN/TAZOBACTAM ALONE AS EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC CANCER PATIENTS : A PROSPECTIVE, RANDOMISED, MULTI-CENTRE, STUDY. | |||||||||||||
Medical condition: Neutropenic, febrile cancer patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021438-68 | Sponsor Protocol Number: C10-109-03 | Start Date*: 2010-08-18 | |||||||||||
Sponsor Name:Lytix Biopharma AS | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, Phase IIa pilot study to evaluate the safety, tolerability and efficacy of Lytixar™ (LTX-109) in patients with uncomplicated, Gram-positive, skin inf... | |||||||||||||
Medical condition: Uncomplicated, Gram-positive skin infections | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000366-35 | Sponsor Protocol Number: RG_09-121 | Start Date*: 2011-09-15 | |||||||||||
Sponsor Name:University of Birmingham [...] | |||||||||||||
Full Title: Tackling Early Morbidity and Mortality in myeloma: assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections | |||||||||||||
Medical condition: Infections during early symptomatic multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000484-28 | Sponsor Protocol Number: LRS114688 | Start Date*: 2011-08-15 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | ||||||||||||||||||
Full Title: A randomised, double-blind, dose-finding, multicenter study of the safety, tolerability, and efficacy of GSK2251052 therapy compared to imipenem-cilastatin in the treatment of adult subjects with f... | ||||||||||||||||||
Medical condition: Complicated Urinary tract infections (cUTI) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GR (Prematurely Ended) HU (Completed) ES (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000546-30 | Sponsor Protocol Number: Rempex-506 | Start Date*: 2015-04-21 | |||||||||||||||||||||||||||||||
Sponsor Name:Rempex Pharmaceuticals, Inc. | |||||||||||||||||||||||||||||||||
Full Title: A PHASE 3, MULTI-CENTER, RANDOMIZED, OPEN-LABEL STUDY OF CARBAVANCE (MEROPENEM/RPX7009) VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH SELECTED SERIOUS INFECTIONS DUE TO CARBAPENEM RESISTANT ENTERO... | |||||||||||||||||||||||||||||||||
Medical condition: serious infections, specifically complicated urinary tract infection (cUTI) or acute pyelonephritis (AP), complicated intra-abdominal infections (cIAI), hospital acquired bacterial pneumonia (HABP... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) IT (Completed) ES (Completed) GR (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000726-21 | Sponsor Protocol Number: D4280C00006 | Start Date*: 2012-09-11 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant G... | ||||||||||||||||||
Medical condition: cUTI, Complicated Urinary Tract Infection, cIAI, Complicated intra-abdominal infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) CZ (Completed) ES (Completed) GR (Completed) BG (Completed) HU (Completed) IT (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
